Keeping AI in Check: The UK’s New Continuous Monitoring Rule

AI DiagnosticsAI TherapyWearables

Imagine a medical device that learns and adapts—now imagine it being watched 24/7. That’s the UK’s bold new plan for AI health tech.

TL;DR
• The UK will require continuous monitoring of AI medical devices after approval.
• A full implementation plan will be released by spring 2027.
• The move positions the UK as a global leader in AI health regulation.

Summary
The UK Medicines and Healthcare products Regulatory Agency (MHRA) will require continuous post‑approval monitoring for AI‑based medical devices, shifting from a single safety check to ongoing surveillance. The government has pledged to adopt all 44 recommendations from the recent AI‑device review and will publish an implementation roadmap by spring 2027, with a draft due by year‑end. Lawrence Tallon highlighted the need to manage non‑deterministic algorithms that evolve during clinical use.
• Publish a detailed post‑market surveillance framework by spring 2027.
• Integrate mandatory lifecycle monitoring checkpoints for AI devices across NHS trusts.
• Establish transparent reporting channels for clinicians to flag algorithmic drift.
• Require developers to submit regular impact assessments covering data handling and bias mitigation.
• Create a redress mechanism for patients affected by AI‑driven diagnostic errors.

The forthcoming plan will set specific delivery targets and timelines, ensuring each regulatory change is operationalised within the NHS. The MHRA’s AI Airlock program will open its third phase, focusing on real‑world performance data and iterative risk evaluation after devices enter clinical practice. International regulators are already seeking guidance from the UK model, positioning Britain as a pioneer in comprehensive AI‑medical governance.

Key operational steps include mandatory documentation of algorithmic updates, public disclosure of performance metrics, and routine audits by independent ethicists. Data protection protocols will be reinforced to safeguard patient information throughout the device’s lifecycle. Stakeholder consultations will involve clinicians, patient groups, and technology experts to anticipate unintended harms and define mitigation strategies.

By embedding continuous oversight, transparent reporting, and stakeholder engagement, the UK aims to balance rapid AI innovation with patient safety and public trust. The approach promises clearer accountability, faster identification of safety issues, and a structured pathway for responsible AI deployment in healthcare.

Will continuous oversight become the new standard for AI medical devices worldwide?